The Society of Family Planning is relieved by the Supreme Court (SCOTUS) decision in United States Food and Drug Administration (FDA) v Alliance for Hippocratic Medicine (AHM). In a unanimous decision, the Court held that AHM, the plaintiffs, did not have standing. This means that the case will be sent back to the lower court to decide whether to dismiss the claims brought by AHM.

Research

In pursuit of our vision of just and equitable abortion informed by science, the Society supports and uplifts research regarding the safety and efficacy of medication abortion.

• Increasing access to medication abortion
• Innovations in medication abortion service delivery
• Capturing tradeoffs in abortion care
• Science Says: Telehealth medication abortion is safe and effective
• #WeCount quarterly reports on the changes in abortion volumes following the Dobbs ruling

Clinical guidance

To support clinicians who administer medication abortion, the Society provides evidence-informed and person-centered guidance. 

• SFP clinical recommendation: Medication abortion between 14 0/7 and 27 6/7 weeks of gestation
• SFP interim clinical recommendation: Self-managed abortion
• Medication abortion up to 70 days of gestation
• Medication abortion with misoprostol-only: A sample protocol

Learning

The Society supports ongoing learning about medication abortion for clinicians, scholars, and advocates.

• Abortion Pill CME
• SFP Source for Science Podcast
• Medication abortion between 14 0/7 and 27 6/7 weeks of gestation course
• Self-managed abortion: What clinicians need to know course
• Misoprostol alone for medication abortion: A safe and effective option

Media/advocacy contact information

For media or partnership inquiries, contact Jenni Villavicencio, MD, MPP, Senior Director of Public Affairs and Advocacy at JVillavicencio@SocietyFP.org.